SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT
  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                           October 14, 2015
                            Date of Report
                     (Date of Earliest Event Reported)

                  AMCHI GENDYNAMY SCIENCE CORPORATION
            (Exact Name of Registrant as Specified in its Charter)

                PRETTY VALLEY ACQUISITION CORPORATION
             (Former Name of Registrant as Specified in its Charter)

Delaware                       000-55224                  47-1360654
(State or other         (Commission File Number)       (IRS Employer
jurisdiction                                           Identification No.)
of incorporation)
                           650 Tamarack
                      Brea, California 92821
             (Address of principal executive offices) (zip code)

                           626-715-9695
         (Registrant's telephone number, including area code

                       215 Apolena Avenue
                Newport Beach, California 92662
      (Former Address of Principal Executive Offices)

ITEM 3.02 Unregistered Sales of Equity Securities

     On October 15, 2015, Amchi Gendynamy Science Corporation (formerly
Pretty Valley Acquisition Corporation) (the "Registrant" or the "Company")
issued 20,000,000 shares of its common stock pursuant to Section 4(2) of
the Securities Act of 1933 at par representing 97.5% of the total
outstanding 20,500,000 shares of common stock as follows:

                             20,000,000          Wisdom Qiao

     With the issuance of the stock and the redemption of 19,500,000
shares of stock (discussed below), the Company effected a change in its
control and the new majority shareholder(s) elected new management of
the Company.  The Company may develop its business plan by future
acquisitions or mergers but no agreements have been reached regarding
any acquisition or other business combination.  The Company changed
its name as part of the change in control.  If the Company makes any
acquisitions, mergers or other business combination, the Company will
file a Form 8-K but until such time the Company remains a shell company.

ITEM 5.01     Changes in Control of Registrant

     On October 14, 2015, the following events occurred which resulted
in a change of control of the Registrant:

              1.  The Registrant redeemed an aggregate of 19,500,000 of
 the then 20,000,000 shares of outstanding stock at a redemption price
of $.0001 per share for an aggregate redemption price of $1,950.

              2.   The then current officers and directors resigned.

              3.   New officer(s) and director(s) were appointed and elected.

    The disclosure required by Item 5.01(a)(8) of Form 8-K was previously filed
with the Securities and Exchange Commission on Form 10-12G filed on June 18,
2014 as amended and supplemented by the information contained in this report.

    The Registrant intends to present and market a new gene editing theory
named Microdynamist that it has identified through years of research.  This
gene principle can be used to repair human DNA mutation problems.  The Company
has identified the process and has experimentally designed technology capable
of offering multidimensional energy recovery therapy to repair individual
human genetic deformations.  The Company understands that its empirical
evidence shows that the proper application of energy at known frequencies
and wave forms on disordered or disrupted life forms, based on specific
dimensions within the basic DNA, can dynamically edit genes.  The Company
has a patent pending on its gene dynamic recovery technology.

ITEM 5.02     Departure of Directors or Principal Officers;
              Election of Directors

    On October 14, 2015 the following events occurred:

    James M. Cassidy resigned as the Registrant's president, secretary
and director.

    James McKillop resigned as the Registrant's vice president and
director.

     Wisdom Qiao was named director of the Registrant.

     Wisdom Qiao was appointed Chief Executive Officer and Treasurer
of the Registrant.

     Wisdom Qiao  serves as the sole director and officer of the Registrant.
She is a scientist and successful entrepreneur.  Ms. Qiao graduated from
China's Huaxi Medical University undergraduate program.  She spent two years
in the China Army Secondary Medical University and served as the chief
pharmacist in the China Army General Hospital.  Since 2003, Ms. Qiao has
worked on research and development of the gene dynamic principal and
gene editing.  Through her research, she discovered the dynamic
principle of gene editing under DNA equations and created the new
theory as Microdynamism.  As an entrepreneur, during the 1990s and
until 2003, Ms. Qiao worked Prudential Securities and Merrill Lynch
in Hong Kong and the U.S.  She was one of the first to bring
overseas private equity funds into China and was co-founder of
the first private equity fund in China, now a 30 billion RMB fund.


                    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunder duly authorized.


                         AMCHI GENDYNAMY SCIENCE CORPORATION


Date: October 20, 2015
                                       Wisdom Qiao
                                       Chief Executive Office